ZORYVE® (roflumilast) is a once-daily and steroid-free prescription topical
CREAM & FOAM FORMULATIONS

Patient-friendly
cream and foam
formulations

CREAM AND FOAM
FORMULATED WITH PURPOSE
ZORYVE was designed for easy, once-daily use1,2
Moisturizing properties1,10,12-14*
  • A novel, water-based emollient formulation
Drug delivery without disrupting
the skin barrier1,2,12,14,15
  • No penetration enhancers
  • No ceramide-stripping properties
No known sensitizers or irritants1,2
  • No fragrances, ethanol, or propylene glycol
Low rates of stinging or burning5†
ZORYVE (roflumilast) cream 0.15%, ZORYVE (roflumilast) foam 0.3% and ZORYVE (roflumilast) cream 0.3%
ZORYVE (roflumilast) cream 0.15%, ZORYVE (roflumilast) foam 0.3% and ZORYVE (roflumilast) cream 0.3%

Mild to Moderate
Atopic Dermatitis
Cream 0.15%
Down to 6 years old

ZORYVE (roflumilast) cream 0.15%, ZORYVE (roflumilast) foam 0.3% and ZORYVE (roflumilast) cream 0.3%ZORYVE (roflumilast) cream 0.15%, ZORYVE (roflumilast) foam 0.3% and ZORYVE (roflumilast) cream 0.3%

Seborrheic
Dermatitis
Foam 0.3%
Down to 9 years old

ZORYVE (roflumilast) cream 0.15%, ZORYVE (roflumilast) foam 0.3% and ZORYVE (roflumilast) cream 0.3%

Plaque
Psoriasis
Cream 0.3%
Down to 6 years old

*Demonstrated in clinical trials of patients with atopic dermatitis.

†Low rates of hot tingling/stinging sensation reported in patient-rated tolerability assessments 10–15 minutes after first application. For atopic dermatitis: 1.6% with ZORYVE (n=883) vs 2.0% with vehicle (n=451). For seborrheic dermatitis in STRATUM: 1.3% with ZORYVE (n=304) vs 1.3% with vehicle (n=152). For plaque psoriasis: 0.4% with ZORYVE (n=562) vs 0.0% with vehicle (n=301).

FIND PATIENT
ACCESS SUPPORT 

Actor
portrayal

REQUEST A
REPRESENTATIVE